Literature search services are currently unavailable. During our hosting provider's UPS upgrade we experienced a hardware failure and are currently working to resolve the issue.

Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.

Despite remarkable responses to the tyrosine kinase inhibitor imatinib, CML patients are rarely cured by this therapy perhaps due to imatinib refractoriness of leukemia-initiating cells (LICs). Evidence for this is limited because of poor engraftment of human CML-LICs in NOD-SCID mice and nonphysiologic expression of oncogenes in retroviral transduction mouse models. To address these challenges, we generated mice bearing conditional knockin alleles of two human oncogenes: HIP1/PDGFbetaR (H/P) and AML1-ETO (A/E). Unlike retroviral transduction, physiologic expression of H/P or A/E individually failed to induce disease, but coexpression of both H/P and A/E led to rapid onset of a fully penetrant, myeloproliferative disorder, indicating cooperativity between these two alleles. Although imatinib dramatically decreased disease burden, LICs persisted, demonstrating imatinib refractoriness of LICs.

Pubmed ID: 19647224


  • Oravecz-Wilson KI
  • Philips ST
  • Yilmaz OH
  • Ames HM
  • Li L
  • Crawford BD
  • Gauvin AM
  • Lucas PC
  • Sitwala K
  • Downing JR
  • Morrison SJ
  • Ross TS


Cancer cell

Publication Data

August 4, 2009

Associated Grants

  • Agency: NCI NIH HHS, Id: CA009676
  • Agency: NCI NIH HHS, Id: R01 CA082363
  • Agency: NCI NIH HHS, Id: R01 CA082363-01A1
  • Agency: NCI NIH HHS, Id: R01 CA082363-02
  • Agency: NCI NIH HHS, Id: R01 CA082363-03
  • Agency: NCI NIH HHS, Id: R01 CA082363-04
  • Agency: NCI NIH HHS, Id: R01 CA082363-05
  • Agency: NCI NIH HHS, Id: R01 CA098730
  • Agency: NCI NIH HHS, Id: R01 CA098730-01
  • Agency: NCI NIH HHS, Id: R01 CA098730-04S1
  • Agency: NCI NIH HHS, Id: R01 CA098730-05A1
  • Agency: NCI NIH HHS, Id: R01 CA82363-03
  • Agency: Howard Hughes Medical Institute, Id:

Mesh Terms

  • Animals
  • Antineoplastic Agents
  • Benzamides
  • Core Binding Factor Alpha 2 Subunit
  • DNA-Binding Proteins
  • Disease Models, Animal
  • Drug Resistance, Neoplasm
  • Gene Knock-In Techniques
  • Genotype
  • Hematopoietic Stem Cells
  • Humans
  • Leukemia, Myelomonocytic, Chronic
  • Mice
  • Mice, Transgenic
  • Myeloproliferative Disorders
  • Oncogene Proteins, Fusion
  • Piperazines
  • Pyrimidines
  • Spleen